Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Effect of Quadro-Iliac Plane Block on Recovery After Laparoscopic Hysterectomy (QIPB-TLH)

11. november 2026 oppdatert av: Betul Kozanhan, Konya Meram State Hospital

Effect of Quadro-Iliac Plane Block on Postoperative Quality of Recovery in Patients Undergoing Laparoscopic Hysterectomy: A Prospective, Randomized, Controlled Clinical Trial

This prospective, randomized, controlled clinical trial aims to evaluate the effect of an ultrasound-guided bilateral quadro-iliac plane block (QIPB) on postoperative recovery quality in patients undergoing elective total laparoscopic hysterectomy.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Total laparoscopic hysterectomy (TLH) is a minimally invasive surgical procedure; however, patients may experience postoperative pain originating from abdominal incisions, visceral manipulation, and pneumoperitoneum-related irritation. Inadequate postoperative pain management may negatively affect patient comfort, early mobilization, and overall quality of recovery. Although opioids provide effective analgesia, their use may be associated with nausea, vomiting, sedation, and other adverse effects. Therefore, multimodal and opioid-sparing analgesic strategies are important components of perioperative care.

The quadro-iliac plane block (QIPB) is an ultrasound-guided fascial plane block targeting the anatomical plane near the caudal attachment of the quadratus lumborum muscle to the iliac crest. Previous clinical studies have suggested that QIPB may improve postoperative analgesia and reduce opioid requirements in selected surgical populations. However, its effect on postoperative recovery quality following total laparoscopic hysterectomy remains to be investigated.

Studietype

Intervensjonell

Registrering (Antatt)

60

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Hunn

Beskrivelse

Inclusion Criteria:

  • Female patients aged 18 years or older.
  • Scheduled for elective total laparoscopic hysterectomy.
  • American Society of Anesthesiologists (ASA) physical status I-III.
  • Body weight of at least 55 kg.
  • Ability to communicate in Turkish and reliably complete the Turkish version of the Quality of Recovery-15 questionnaire (QoR-15T).
  • Provision of written informed consent after receiving information about the study.

Exclusion Criteria:

  • Refusal to provide informed consent or withdrawal of consent.
  • Any contraindication to regional anesthesia.
  • Infection at the intended block site or anatomical conditions preventing safe needle insertion.
  • Severe hypersensitivity or contraindication to local anesthetics or standard/rescue analgesic medications specified in the study protocol.
  • Regular opioid use or opioid use disorder.
  • Regular analgesic use for chronic pain lasting longer than three months.
  • Clinically significant hepatic or renal insufficiency.
  • Pregnancy, postpartum period, or breastfeeding.
  • Cognitive or communication impairment preventing reliable completion of QoR-15T or postoperative pain assessments.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: QIPB Group

Patients will receive bilateral ultrasound-guided quadro-iliac plane blocks with 20 mL of 0.25% bupivacaine per side in addition to standard multimodal analgesia.

After surgery and before extubation, bilateral QIPB will be performed under ultrasound guidance. A total of 40 mL of 0.25% bupivacaine (20 mL per side) will be injected into the quadro-iliac fascial plane.

Andre navn:
  • QIPB
Ingen inngripen: Control Group

Patients will receive standard general anesthesia and postoperative multimodal analgesia without a regional block.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Quality of Postoperative Recovery Assessed by the QoR-15T Score
Tidsramme: 24 hours postoperatively

Postoperative quality of recovery will be assessed using the validated Turkish version of the 15-item Quality of Recovery questionnaire (QoR-15T). The questionnaire consists of 15 items, each scored from 0 to 10, yielding a total score ranging from 0 to 150. Higher scores indicate better quality of recovery. The primary outcome is the total QoR-15T score at 24 hours postoperatively, compared between the bilateral Quadro-Iliac Plane Block (QIPB) group and the control group.

24 hours postoperatively

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Postoperative Pain Intensity at Rest
Tidsramme: PACU admission and 2, 4, 6, 8, 12, and 24 hours postoperatively

Postoperative pain intensity at rest will be assessed using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity.

PACU admission and 2, 4, 6, 8, 12, and 24 hours postoperatively
Postoperative Pain Intensity During Movement or Coughing
Tidsramme: PACU admission and 2, 4, 6, 8, 12, and 24 hours postoperatively

Postoperative pain intensity during movement or coughing will be assessed using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity.

PACU admission and 2, 4, 6, 8, 12, and 24 hours postoperatively
Time to First Rescue Analgesia
Tidsramme: Within 24 hours postoperatively

Time from admission to the post-anesthesia care unit (PACU) to the first administration of rescue analgesia will be recorded in minutes.

Within 24 hours postoperatively
Time to First Opioid Analgesia
Tidsramme: Within 24 hours postoperatively

Time from admission to the post-anesthesia care unit (PACU) to the first administration of intravenous opioid will be recorded in minutes.

Within 24 hours postoperatively
Total Postoperative Tramadol Consumption
Tidsramme: First 24 hours postoperatively

The total cumulative dose of intravenous opioid administered during the first 24 hours after surgery will be recorded.

First 24 hours postoperatively
Postoperative Nausea and Vomiting
Tidsramme: Within 24 hours postoperatively

Postoperative nausea and vomiting (PONV) will be assessed using a 5-point Verbal Descriptive Scale (VDS), ranging from 0 to 4 (0 = no nausea or vomiting, 1 = mild nausea, 2 = moderate nausea or vomiting, 3 = frequent vomiting, and 4 = severe vomiting). Higher scores indicate more severe symptoms.

Within 24 hours postoperatively
Patient Satisfaction with Postoperative Analgesia
Tidsramme: 24 hours postoperatively

Patient satisfaction with postoperative pain management will be assessed at 24 hours after surgery using a 5-point Likert scale ranging from 1 to 5. Higher scores indicate greater patient satisfaction with postoperative analgesia.

24 hours postoperatively

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

8. november 2026

Primær fullføring (Antatt)

8. februar 2027

Studiet fullført (Antatt)

8. mars 2027

Datoer for studieregistrering

Først innsendt

11. november 2026

Først innsendt som oppfylte QC-kriteriene

11. november 2026

Først lagt ut (Faktiske)

18. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

11. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • KSH-QIPB-TLH-2026-01

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .